Five Prime Therapeutics Inc (NASDAQ:FPRX) has earned a consensus rating of “Hold” from the ten analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $67.75.

Several analysts have recently weighed in on the company. Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 price objective for the company in a report on Monday, October 16th. Royal Bank of Canada boosted their target price on Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, November 6th. BMO Capital Markets boosted their target price on Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 7th. Jefferies Group reaffirmed a “buy” rating and set a $52.00 target price on shares of Five Prime Therapeutics in a research report on Tuesday, September 12th. Finally, ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

Shares of Five Prime Therapeutics (NASDAQ:FPRX) traded down $1.09 during trading on Thursday, hitting $20.89. The stock had a trading volume of 856,567 shares, compared to its average volume of 821,393. Five Prime Therapeutics has a twelve month low of $20.52 and a twelve month high of $53.89.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.19). The firm had revenue of $8.33 million during the quarter, compared to analyst estimates of $16.16 million. Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.72) EPS. analysts forecast that Five Prime Therapeutics will post -5.56 EPS for the current year.

In other news, Director William R. Ringo sold 600 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total transaction of $27,198.00. Following the sale, the director now directly owns 600 shares of the company’s stock, valued at $27,198. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William R. Ringo sold 2,000 shares of the business’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $38.00, for a total value of $76,000.00. Following the sale, the director now directly owns 2,000 shares in the company, valued at $76,000. The disclosure for this sale can be found here. Insiders have sold 4,400 shares of company stock worth $175,666 over the last ninety days. 6.50% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the stock. Oppenheimer & Co. Inc. acquired a new position in Five Prime Therapeutics during the third quarter valued at $223,000. Dupont Capital Management Corp acquired a new position in Five Prime Therapeutics during the third quarter valued at $341,000. Legal & General Group Plc raised its position in Five Prime Therapeutics by 3.1% during the second quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 287 shares during the period. Virtu KCG Holdings LLC acquired a new position in Five Prime Therapeutics during the second quarter valued at $331,000. Finally, Tudor Investment Corp ET AL raised its position in Five Prime Therapeutics by 49.4% during the second quarter. Tudor Investment Corp ET AL now owns 11,999 shares of the biotechnology company’s stock valued at $361,000 after buying an additional 3,966 shares during the period. 83.80% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/14/five-prime-therapeutics-inc-fprx-given-consensus-recommendation-of-hold-by-analysts.html.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.